Molecular Oncology Department Metrics
View the grants and publications from the Department of Molecular Oncology.
Grants
- Intrinsic Disorder Controls the Function 0f p53 and Other Cancer Associated IDPs
Sponsor: Univ of South Florida
PI (MPI):Chen, J. - CPTAC Phase III
Sponsor: Nat Institutes of Health
PI:Koomen, J. - Ubiquitination-dependent Regulation of BRAF Function in Melanoma
Sponsor: Amer Cancer Society
PI:Wan, L. - Anti-tumor Potential of Temperature-Sensitive p53 Mutants
Sponsor: Nat Institutes of Health
PI (Contact):Chen, J.,PI:Mann, M. - Integrated Program in Cancer and Data Science
Sponsor: Nat Institutes of Health
PI (Contact):Cress, D.,PI (MPI):Flores, E.,PI (MPI):Fridley, B. - CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
Sponsor: Nat Institutes of Health
PI:Kissil, J. - Discovery of p53 inhibitors for reducing toxicity of chemotherapy
Sponsor: Florida Biomedical Research Program (FBRP)
PI:Chen, J. - Identifying Metabolic Vulnerabilities in Lung Cancer
Sponsor: Nat Institutes of Health
PI (Contact):Flores, E.,PI (MPI):Haura, E.,Project PI:DeNicola, G.,Project PI:Rodriguez, P.,Project PI:Cleveland, J.,Core PI/Director:Fridley, B.,Core PI/Director:Cress, D.,Core PI/Director:Koomen, J. - Direct Control of the human CMG Helicase by Myc and Rb
Sponsor: Nat Institutes of Health
PI:Alexandrow, M. - Exploring miR-29 in Melanoma Progression and Prevention
Sponsor: Nat Institutes of Health
PI:Karreth, F. - Targeting altered phosphatase-dependent signaling to overcome the inefficacy of targeted therapy in myeloproliferative neoplasms
Sponsor: Nat Institutes of Health
PI:Reuther, G. - Propionate metabolism as an essential metabolic adaptation for tumor progression
Sponsor: Nat Institutes of Health
PI:Gomes, A. - Chromosome 1q ceRNAs in melanoma progression and metastasis
Sponsor: Nat Institutes of Health
PI:Karreth, F. - Molecular Drivers of Lung Cancer in Hispanics
Sponsor: Nat Institutes of Health
PI (Contact):Cress, D.,PI (MPI):Teer, J. - Aging as a selective pressure that drives tumor progression
Sponsor: Nat Institutes of Health
PI:Gomes, A. - Elucidating PTEN tumor suppression in melanoma
Sponsor: Florida Biomedical Research Program (FBRP)
PI:Karreth, F. - Biophysical basis for enzyme mediated deglycation in protein repair
Sponsor: Nat Institutes of Health
PI:Binning, J. - Characterizing oncogenic function of ITCH in melanoma
Sponsor: Nat Institutes of Health
PI:Wan, L. - Mechanisms of age-induced chemotherapeutic resistance in lung cancer
Sponsor: Amer Lung Assoc
PI:Gomes, A. - Characterization of the Oncogenic Potential of circRNAs in Melanoma
Sponsor: Nat Institutes of Health
PI:Karreth, F. - Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas
Sponsor: Nat Institutes of Health
PI (MPI):Cress, D. - Elucidating the Oncogenic Role of sMAF Proteins in Melanoma
Sponsor: Amer Cancer Society
PI:Karreth, F. - Allosteric Regulation of MDMX by Protein Disorder
Sponsor: Nat Institutes of Health
PI (Contact):Chen, J. - NAD+: A Missing Link Between Aging and Pancreatic Tumorigenesis
Sponsor: Phi Beta Psi
PI:Gomes, A. - Elucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targets
Sponsor: Nat Institutes of Health
PI:Kissil, J. - Establishing the functional differences between variant oncogenic KRAS alleles and identification of allele-selective inhibitors
Sponsor: Florida Biomedical Research Program (FBRP)
PI:Kissil, J. - Pilot Study of Bladder Cancer Chemo Sensitization by Hypothermia
Sponsor: Moffitt Cancer Center
PI (Contact):Chen, J.,PI:Huang, J.,PI:Li, R.,PI:Spiess, P. - Novel Mouse Models of Uveal Melanoma
Sponsor: Melanoma Research Alliance (MRA)
PI:Karreth, F. - Exploring the Impact of HSP90 Inhibition on Antigen Presentation and Anti-Tumor Immune Responses
Sponsor: Nat Institutes of Health
PI:Jaeger, A. - Epigenetic mechanisms that underlie breast cancer dormancy
Sponsor: Amer Cancer Society
PI:Gomes, A. - RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
Sponsor: Nat Institutes of Health
PI:Mann, K. - Assessing novel therapeutics against RAS activation in models of myeloproliferative neoplasm and JAK2 inhibitor resistance
Sponsor: Revolution Medicines Inc
PI:Reuther, G. - The role of HPV E1 in regulating the NRF2-KEAP1 pathway
Sponsor: Nat Institutes of Health
PI:Binning, J. - Restoring FZR1 Tumor Suppressor Function in Human Cancers
Sponsor: Florida Biomedical Research Program (FBRP)
PI:Wan, L. - Understanding the mechanisms by which STK11 loss in lung cancer leads to immune invasion
Sponsor: Florida Biomedical Research Program (FBRP)
PI:Cress, D. - FGF-19 as a mechanistic link that enable metastasis in old hosts
Sponsor: Moffitt Cancer Center
PI:Gomes, A. - Mapping the antigenic landscape of intraductal papillary mucinous neoplasm (IPMN)
Sponsor: Moffitt Cancer Center
PI:Jaeger, A.,CO-PI:Fleming, J.
Publications
- Mooradian MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, Parikh A, Buchbinder EI, Cohen JV, Lawrence DP, Shapiro GI, Keer H, Chen HX, Ivy SP, Smalley KSM, Koomen JM, Sullivan RJ. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 Jun.129(12):1904-1918. Pubmedid: 37042037.
- Hu Q, Liao Y, Cao J, Fang B, Yun S, Kinose F, Haura E, Lawrence H, Doebele R, Koomen J, Rix U. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem. 2023 Jun.24(11):e202200766. Pubmedid: 36922348.
- Yoon SJ, Combs JA, Falzone A, Prieto-Farigua N, Caldwell S, Ackerman HD, Flores ER, DeNicola GM. Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. Cancer Res. 2023 May.83(9):1426-1442. Pubmedid: 36862034. Pmcid: PMC10152234.
- Ilter D, Drapela S, Schild T, Ward NP, Adhikari E, Low V, Asara J, Oskarsson T, Lau EK, DeNicola GM, McReynolds MR, Gomes AP. NADK-mediated de novo NADP(H) synthesis is a metabolic adaptation essential for breast cancer metastasis. Redox Biol. 2023 May.61:102627. Pubmedid: 36841051. Pmcid: PMC9982641.
- Drapela S, Gomes AP. The aging lung reawakens dormant tumor cells. Nat Cancer. 2023 Apr.4(4):442-443. Pubmedid: 37106111.
- Trinh T, Adams WA, Calescibetta A, Tu N, Dalton R, So T, Wei M, Ward G, Kostenko E, Christiansen S, Cen L, McLemore A, Reed K, Whiting J, Gilvary D, Blanco NL, Segura CM, Nguyen J, Kandell W, Chen X, Cheng P, Wright GM, Cress WD, Liu J, Wright KL, Wei S, Eksioglu EA. CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience. 2023 Apr.26(4):106443. Pubmedid: 37070068. Pmcid: PMC10105289.
- DeBlasi JM, Falzone A, Caldwell S, Prieto-Farigua N, Prigge JR, Schmidt EE, Chio IIC, Karreth FA, DeNicola GM. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. Cancer Res. 2023 Apr. Pubmedid: 37062029.
- Amirifar P, Kissil J. The role of Motin family proteins in tumorigenesis-an update. Oncogene. 2023 Apr.42(16):1265-1271. Pubmedid: 36973516.
- Ross KE, Zhang G, Akcora C, Lin Y, Fang B, Koomen J, Haura EB, Grimes M. Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer. PLoS Comput Biol. 2023 Mar.19(3):e1010690. Pubmedid: 36996232. Pmcid: PMC10089347.
- Yousefi H, Khosla M, Lauterboeck L, Okpechi SC, Worthylake D, Garai J, Zabaleta J, Guidry J, Zarandi MA, Wyczechowska D, Jayawickramarajah J, Yang Q, Kissil J, Alahari SK. Correction to: A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming. Oncogene. 2023 Mar.42(11):859. Pubmedid: 36759576.
- Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 Feb.4(2):222-239. Pubmedid: 36690875. Pmcid: PMC9970875.
- Liao Y, Chin Chan S, Welsh EA, Fang B, Sun L, Schönbrunn E, Koomen JM, Duckett DR, Haura EB, Monastyrskyi A, Rix U. Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target. Acs Chem Biol. 2023 Feb.18(2):251-264. Pubmedid: 36630201.
- Xiang S, Reed DR, Alexandrow MG. The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations. Oncogene. 2023 Feb.42(7):473-490. Pubmedid: 36522488. Pmcid: PMC9948756.
- Soupir AC, Tian Y, Stewart PA, Nunez-Lopez YO, Manley BJ, Pellini B, Bloomer AM, Zhang J, Mo Q, Marchion DC, Liu M, Koomen JM, Siegel EM, Wang L. Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. Int J Mol Sci. 2023 Jan.24(3). Pubmedid: 36768152. Pmcid: PMC9916336.
- Welsch JT, Smalley TB, Matlack JK, Avalon NE, Binning JM, Johnson MP, Allcock AL, Baker BJ. Tuaimenals B-H, Merosesquiterpenes from the Irish Deep-Sea Soft Coral Duva florida with Bioactivity against Cervical Cancer Cell Lines. J Nat Prod. 2023 Jan.86(1):182-190. Pubmedid: 36580354. Pmcid: PMC9887596.
- Sarcar B, Fang B, Izumi V, Nunez-Lopez Y, Tassielli A, Pratley R, Jeong D, Permuth JB, Koomen JM, Fleming JB, Stewart PA. A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer-Associated Stellate Cell Small Extracellular Vesicles. Mol Cell Proteomics. 2022 Dec.21(12):100438. Pubmedid: 36332889. Pmcid: PMC9792568.
- Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 Dec.114(12):1619-1627. Pubmedid: 36053203. Pmcid: PMC9745425.
- Yousefi H, Khosla M, Lauterboeck L, Okpechi SC, Worthylake D, Garai J, Zabaleta J, Guidry J, Zarandi MA, Wyczechowska D, Jayawickramarajah J, Yang Q, Kissil J, Alahari SK. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming. Oncogene. 2022 Nov.41(47):5076-5091. Pubmedid: 36243802.
- Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U. Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer. J Biol Chem. 2022 Nov.298(11):102550. Pubmedid: 36183837. Pmcid: PMC9636579.
- Fenton M, Borcherds W, Chen L, Anbanandam A, Levy R, Chen J, Daughdrill G. The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX. J Mol Biol. 2022 Nov.434(22):167844. Pubmedid: 36181774. Pmcid: PMC9644833.
- Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, Kinsey CG, Adams DJ, Grossmann A, Mann MB, McMahon M. Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Res. 2022 Nov.82(22):4261-4273. Pubmedid: 36112789. Pmcid: PMC9664136.
- Amini AP, Kirkpatrick JD, Wang CS, Jaeger AM, Su S, Naranjo S, Zhong Q, Cabana CM, Jacks T, Bhatia SN. Multiscale profiling of protease activity in cancer. Nat Commun. 2022 Oct.13(1):5745. Pubmedid: 36192379. Pmcid: PMC9530178.
- Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234. Pmcid: PMC9662872.
- Madanayake TW, Welsh EA, Darville LNF, Koomen JM, Chalfant CE, Haura EB, Robinson TJ. Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition. Nucleic Acid Ther. 2022 Oct.32(5):391-400. Pubmedid: 35861718. Pmcid: PMC9595651.
- Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
- Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022 Oct.85:123-154. Pubmedid: 33992782.
- Yang Y, Peng Z, Flores ER, Kleinerman ES. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming. Cancers (Basel). 2022 Sep.14(17). Pubmedid: 36077845. Pmcid: PMC9454976.
- Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I, Elemento O, Du D, Yu X, Karreth FA. Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis. Cancer Res. 2022 Sep.82(17):3016-3031. Pubmedid: 36052492.
- Ragland NH, Compo NR, Wiltshire N, Shepard A, Troutman S, Kissil JL, Engelman RW. Housing and Husbandry Alternatives for Naked Mole Rat Colonies Used in Research Settings. J Am Assoc Lab Anim Sci. 2022 Sep.61(5):412-418. Pubmedid: 35944976. Pmcid: PMC9536831.
- Drapela S, Ilter D, Gomes AP. Metabolic reprogramming: a bridge between aging and tumorigenesis. Mol Oncol. 2022 Sep.16(18):3295-3318. Pubmedid: 35666002. Pmcid: PMC9490145.
- Remsing Rix LL, Sumi NJ, Hu Q, Desai B, Bryant AT, Li X, Welsh EA, Fang B, Kinose F, Kuenzi BM, Chen YA, Antonia SJ, Lovly CM, Koomen JM, Haura EB, Marusyk A, Rix U. IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Sci Signal. 2022 Aug.15(747):eabj5879. Pubmedid: 35973030. Pmcid: PMC9528501.
- Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I, Elemento O, Du D, Yu X, Karreth FA. Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis. Cancer Res. 2022 Aug. Pubmedid: 35820070.
- Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35793871. Pmcid: PMC9260835.
- Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan SL, Shalek AK, Spranger S, White FM, Jacks T. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature. 2022 Jul.607(7917):149-155. Pubmedid: 35705813.
- Chitsazzadeh V, Nguyen TN, de Mingo Pulido A, Bittencourt BB, Du L, Adelmann CH, Rivera IO, Nguyen KA, Guerra LD, Davis A, Napoli M, Ma W, Davis RE, Rajapakshe K, Coarfa C, Flores ER, Tsai KY. miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFβR3. J Invest Dermatol. 2022 Jul.142(7):1956-1965.e2. Pubmedid: 34890627. Pmcid: PMC9174350.
